昊海生科(688366.SH)變更超募資金用途 擬4552.22萬元投資奉賢基地一期建設項目
格隆匯5月14日丨昊海生科(688366.SH)公佈,為充分發揮募集資金的使用效率,根據公司實際經營發展的需要,公司擬使用首次公開發行股票募集的3241.18萬元(含利息)剩餘超募資金,以及前次用作永久補充流動資金的1311.04萬元(含利息)超募資金,合計4552.22萬元(含利息)的超募資金,用於建華生物奉賢基地一期建設項目。項目擬總投資額為1.85億元,不足部分公司自籌。
項目實施主體為公司的全資子公司建華生物,建華生物為應對場地搬遷執行該項目。項目建設內容為:改造生產車間以及倉庫、生產輔助等設施,生產各類透明質酸鈉/玻璃酸鈉系列產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.